Trial record 1 of 1 for:
PANBELA CL-SBP-101-04 (ASPIRE)
Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer (ASPIRE)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT05254171 |
|
Recruitment Status :
Recruiting
First Posted : February 24, 2022
Last Update Posted : April 16, 2024
|
Sponsor:
Panbela Therapeutics, Inc.
Information provided by (Responsible Party):
Panbela Therapeutics, Inc.
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Recruiting |
|---|---|
| Estimated Primary Completion Date : | August 29, 2026 |
| Estimated Study Completion Date : | January 1, 2027 |